CROs/Service Providers

Aesica launches new service model

Wednesday, October 14, 2015

Aesica, a U.K.-based global pharmaceutical contract development and manufacturing organization (CDMO), has unveiled a new approach and business model that solves multiple supply-chain challenges at once. The company takes on the management of other CDMOs, while serving as the single, central point of customer contact.

[Read More]

Charles River inks three new collaborations

Friday, October 9, 2015

Charles River Laboratories International has announced new and continuing collaborations with three innovative drug discovery partners funded by the Wellcome Trust. Antabio, an antibacterial drug discovery company; Pcovery, a spin-out company focused on anti-fungals; and the British Columbia Cancer Agency have all extended existing or commenced new agreements with Charles River’s Global Discovery Services business.

[Read More]

PPD awarded Army, BARDA research contracts

Thursday, October 8, 2015

has been awarded two separate U.S. government contracts to improve health outcomes for armed forces service members and to help test the effectiveness of the nation’s stockpile of avian influenza vaccine to safeguard the public.

[Read More]

Merck Millipore, celares collaborate

Monday, October 5, 2015

Merck Millipore, the life science business of German-based Merck, is collaborating with celares, a privately owned biopharmaceuticals company, to provide pegylation services to customers developing protein-based therapeutics and biosimilars. The new service offering enabled by the collaboration includes feasibility studies, process and analytical development and scale-up from milligram to gram quantities required for pilot and subsequent commercial scale.

[Read More]

INC Research gains iCardiac Site Certification

Friday, October 2, 2015

INC Research Holdings, a global phase I to IV CRO, has been certified to use the iCardiac Early Precision QT approach for evaluating the cardiac safety of new compounds in phase I clinical development. INC’s use of iCardiac Early Precision QT may help customers reduce costs, and increase the accuracy, reliability and speed of cardiac safety testing in clinical research.

[Read More]